
An expert discusses trends in pediatric mental health and receipt of treatment.

An expert discusses steps the FDA can take to strengthen and make more airtight their process for approving new opioids.

An expert discusses the effect the pandemic has had on opioid use and related deaths.

A pharmacoepidemiologist offers his comments on the ongoing opioid epidemic.

An expert discusses how allergies can make it easier for viruses to enter the body as well as the association between asthma and COVID-19 severity.

For many patients suffering from depression or anxiety, the added stress of the pandemic has led to a medication change.

Educating patients of the immune system can be helpful in addressing any concerns over getting vaccinated for the flu.

An expert discusses the importance of getting vaccinated for the flu this year as well as strategies healthcare systems are taking to ensure easy access for patients.

Pulmonary conditions like asthma could often lead to the development of chronic cough.

Despite not being able to attend conferences live, there are some advantages to a virtual conference.

Asthma patients have not had higher rates of negative outcomes from COVID-19 than other individuals.

The biologic drug is set to be used as a combination therapy for asthma.

It has been approximately 60 years since a new treatment for coughs has come on the market.

Obese-related asthma is considered one of the more severe asthma phenotypes.

Telemedicine has become an important tool during the COVID-19 pandemic.

Problems using inhalers correctly is an ongoing issue for both pediatric and adult patients.

The congress president shares her favorite sessions, and ideas to integrate virtual setting successes into next year's meeting.

Catch up on this week's biggest headlines in FDA news.

Catch up on this week's biggest headlines in FDA news.

This week, the FDA received an application for a metoclopramide nasal spray and a receptor agonist for hypoactive sexual desire disorder, approved baricitinib on its second try, and granted Priority Review to emicizumab for hemophilia A.

This week, the FDA approved the first standalone prosthetic iris, granted priority review to a pediatric anti-epileptic and a postpartum depression drug, accepted another try from an opioid use disorder drug, and announced new plans against the opioid epidemic.

This week on MDNN: Cinnamon flavoring in e-cigarettes has been found to disrupt the lungs’ anti-bacterial defense system, new hypertension guidelines have increased the condition's prevalence, and the US Congress passed a right-to-try bill.

This week on MDNN: ADHD symptoms are linked to binge and restrictive eating, physicians paid by opioid marketers are more likely to prescribe them, and one-third of nurses work overtime.

This week on MDNN: Stigmatizing phrasing influences patient care, Pokemon GO improves behavioral health, depressed women and men differentiate in gene expression, and fast food can stall a woman's time to pregnancy.

This week on MDNN: Autism Spectrum Disorder rates are rising in the US, handwashing is effective for C. diff prevention, and PROMISE 1 trial results have been reported.

This week on MDNN: Prolonged use of acetaminophen has been linked to an increase in the relative risk of ADHD and ASD, the ANA annual meeting issued 30 new recommendations for disease-modifying therapy for multiple sclerosis and the American Academy of Family Physicians announced a new Well-Being Planner to manage stressors and address burnout.


This week on MDNN: The SELECT-COMPARE trial reported positive results for upadacitinib, older adults in the US are not being tested for HIV, and the shifting trends in US mortality.

This week on MDNN: Physician report being unaware of how many opioids they prescribe, legalized marijuana cuts down on opioid rates in Medicaid patients, Grindr responds to leak they share users' HIV statuses, and the FDA recalls salmonella-containing kratom.

This week on MDNN: Neonatal abstinence syndrome increases by 433% over a decade, CDC reports opioid deaths are driven by synthetic strains, and drug use disorder mortality accounts for 4% of all 2015 deaths.